Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEON study of MB11 versus EU-/US-Opdivo in previously untreated advanced melanoma
2025-521562-95-00Phase 3Authorised
- Sponsor
- mAbxience
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of LY01015 and nivolumab in melanoma (3 arms), sponsored by mAbxience. Primary endpoints: AUC0-336 between Cycle 1 and Cycle 2, AUCss between Cycle 8 and Cycle 9 and 2 more. Planned start Nov 2025; status: authorised.
02
Drugs
LY01015nivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2025-521562-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521562-95-00.